Mesa Laboratories, Inc.
General ticker "MLAB" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $564.3M (TTM average)
Mesa Laboratories, Inc. does not follow the US Stock Market performance with the rate: -8.0%.
Estimated limits based on current volatility of 2.9%: low 76.86$, high 81.44$
Factors to consider:
- Company pays dividends (quarterly): last record date 2025-08-29, amount 0.16$ (Y0.83%)
- Total employees count: 736 (+5.4%) as of 2024
- China accounted for 11.5% of revenue in the fiscal year ended 2024-03-31
- US accounted for 49.2% of revenue in the fiscal year ended 2024-03-31
- Top business risk factors: Economic downturns and volatility, Geopolitical risks, Supply chain disruptions, Cybersecurity threats, Market competition
- Current price 16.7% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [92.63$, 153.59$]
- 2026-03-31 to 2027-03-31 estimated range: [88.49$, 148.23$]
Financial Metrics affecting the MLAB estimates:
- Negative: with PPE of 12.2 at the end of fiscal year the price was very high
- Positive: -3.60 < Operating profit margin, % of 6.78
- Positive: 6.82 < Operating cash flow per share per price, % of 6.97
- Negative: Industry operating cash flow per share per price (median), % of 2.05 <= 5.52
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -0.45
- Positive: 18.93 < Shareholder equity ratio, % of 36.88 <= 41.86
- Negative: Investing cash flow per share per price, % of -0.67 <= -0.66
Short-term MLAB quotes
Long-term MLAB plot with estimates
Financial data
| YTD | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating Revenue | $219.08MM | $216.19MM | $240.98MM |
| Operating Expenses | $215.76MM | $488.26MM | $224.64MM |
| Operating Income | $3.32MM | $-272.07MM | $16.34MM |
| Non-Operating Income | $-3.71MM | $-3.57MM | $-10.38MM |
| Interest Expense | $4.77MM | $5.70MM | $11.86MM |
| R&D Expense | $20.49MM | $19.30MM | $19.52MM |
| Income(Loss) | $-0.39MM | $-275.65MM | $5.96MM |
| Taxes | $-1.32MM | $-21.40MM | $7.93MM |
| Profit(Loss)* | $0.93MM | $-254.25MM | $-1.97MM |
| Stockholders Equity | $393.48MM | $145.39MM | $159.83MM |
| Inventory | $34.64MM | $32.67MM | $25.36MM |
| Assets | $661.83MM | $446.80MM | $433.35MM |
| Operating Cash Flow | $27.98MM | $44.13MM | $46.81MM |
| Capital expenditure | $4.54MM | $2.57MM | $4.50MM |
| Investing Cash Flow | $-9.49MM | $-81.31MM | $-4.50MM |
| Financing Cash Flow | $-33.33MM | $32.84MM | $-44.51MM |
| Earnings Per Share** | $0.17 | $-47.20 | $-0.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.